Hormonal replacement therapy (HRT) in menopausal women has been grown as a result of the potential short-, medium-, and long-term benefits. The magnitude of risks, including breast and endometrial cancer, and thromboembolic events are in continuous evaluation. The association between HRT and risk of venous thromboembolism (VTE) has been the target of a number of controversies. Observational studies have shown that women on HRT have increased risk of VTE, mainly in the first year of use. Methodological limitations, unsuitable control […]